STEVEN WU: Open Payments
NPI 1437519378 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$789 in 32 payments from 11 companies in 2025. Trend: 2023 $105 · 2024 $458 · 2025 $789
Food & beverage: $789
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 6 | $225 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $137 |
| Lilly USA, LLC | 5 | $113 |
| Novo Nordisk Inc | 4 | $72 |
| Abbott Laboratories | 3 | $58 |
| SANOFI-AVENTIS U.S. LLC | 3 | $53 |
| Amgen Inc. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| Astellas Pharma US Inc | 1 | $21 |
| Organon LLC | 1 | $19 |
Products named: JARDIANCE, Yeztugo, MOUNJARO, FREESTYLE LIBRE 3, TZIELD, EVENITY, Wegovy, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
